{"gene":"CD19","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1989,"finding":"CD19 is physically and functionally associated with surface immunoglobulin (sIg) on B cells. Anti-Ig antibodies cause specific, rapid, reversible, and unidirectional co-modulation of CD19, with anti-Ig co-capping and internalizing anti-CD19 mAb, suggesting CD19 is a component of the B cell antigen receptor complex that facilitates signal transduction by sIg-antigen complexes.","method":"Co-modulation assays, co-capping experiments with 15 CD19-specific mAbs and anti-Ig mAbs on mature B cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-modulation with multiple orthogonal antibodies, replicated across multiple B cell types and CD19 epitopes","pmids":["2479707"],"is_preprint":false},{"year":1997,"finding":"CD19 and CD22 have counterregulatory effects on MAP kinase (ERK2, JNK, p38) activation downstream of membrane immunoglobulin (mIg). Co-ligation of CD19 with mIg synergistically amplifies MAP kinase activation, while CD22 suppresses MAP kinase activation when cross-linked to mIg. This regulation is dependent on the proximity of these coreceptors to the antigen receptor.","method":"MAP kinase activation assays with selective co-ligation and cross-linking of CD19 and CD22 with mIg on B cells","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — direct functional assay with multiple kinase readouts and reciprocal co-ligation controls","pmids":["9252120"],"is_preprint":false},{"year":2001,"finding":"CD19 is necessary for efficient activation of Akt kinase following BCR cross-linking or Igβ ligation in B lymphocytes. In the absence of CD19, Akt kinase activity is reduced and transient. Co-ligation of CD19 with surface immunoglobulin leads to dose-dependent augmented Akt activity, placing CD19 as a key regulator of PI3K-dependent Akt survival signaling.","method":"Akt kinase activity assays in CD19-deficient B lymphoma cells and mouse splenic B cells; co-ligation experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct kinase assay in both cell line and primary cells with genetic loss-of-function, replicated with co-ligation","pmids":["11042164"],"is_preprint":false},{"year":2001,"finding":"CD19 deficiency suppresses the hyper-responsive B cell phenotype and autoimmunity (serum autoantibodies, glomerulonephritis) in Lyn-deficient mice, demonstrating that a CD19/Lyn amplification loop is a major regulator of B cell signaling thresholds. Tyrosine phosphorylation of Fyn and BCR-induced Ca2+ responses were dramatically reduced in CD19/Lyn double-deficient B cells.","method":"Compound knockout mouse model (CD19/Lyn double-deficient); immunological phenotyping, Ca2+ flux assays, tyrosine phosphorylation analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple molecular and cellular phenotypic readouts","pmids":["11509585"],"is_preprint":false},{"year":2002,"finding":"CD19 cytoplasmic tyrosines Y482 and Y513 are essential for all major functions of CD19 in vivo, including differentiation of B1 and marginal zone B cells, T-dependent and -independent antibody responses, and germinal center B cell maturation. Mutation of Y482/Y513 reduces proliferation in germinal center B cells.","method":"CD19-knockout mice expressing transgenic CD19 constructs with specific tyrosine mutations; immunological phenotyping in vivo","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 — in vivo site-directed mutagenesis of specific residues combined with comprehensive phenotypic analysis","pmids":["12387743"],"is_preprint":false},{"year":2002,"finding":"CD19 physically associates with Bruton's tyrosine kinase (Btk) following BCR engagement in A20 B cells. CD19 expression maintains Btk in an activated state following BCR engagement, rather than being required for initial Btk phosphorylation. CD19-induced Ca2+ responses require downstream Btk function, and CD19 deficiency combined with Btk mutation (Xid) has additive inhibitory effects.","method":"Co-immunoprecipitation of CD19 and Btk; genetic compound mouse models (CD19−/− × Xid); Ca2+ flux assays; PI3K/Akt activation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus genetic compound mutants with multiple functional readouts","pmids":["12023340"],"is_preprint":false},{"year":2007,"finding":"CD86 signals through CD19 to activate PI3K and increase IgG1 production in B cells. CD28/Ig-mediated signaling increases phosphorylation of Lyn and CD19 and the association of Lyn, Vav, and PI3K with CD19. This effect is absent in CD86- or CD19-deficient B cells, placing CD86→Lyn→CD19 upstream of PI3K in IgG1 regulation.","method":"Co-immunoprecipitation of CD19 with Lyn/Vav/PI3K; adoptive transfer experiments in RAG2-deficient mice with CD86-deficient B cells; in vitro stimulation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus genetic loss-of-function with in vivo reconstitution","pmids":["17641017"],"is_preprint":false},{"year":2009,"finding":"Uncoupling CD21 (complement receptor) from CD19 via knockin mice expressing mutant receptors that bind C3 ligands but cannot signal through CD19 significantly diminishes survival of germinal center B cells and secondary antibody titers, confirming that the physical and functional interaction between CD21/CR and CD19 is necessary for coreceptor activity in humoral immunity.","method":"Knockin mouse model (Cr2 delta/delta gfp); germinal center B cell survival assays; antibody titer measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic uncoupling with defined cellular and humoral phenotypic consequences","pmids":["19706534"],"is_preprint":false},{"year":2010,"finding":"CD19 cytoplasmic tyrosines Y513, Y482, and Y391 are differentially phosphorylated during B cell activation, serving as docking sites for Lyn (Y513), PI3K (Y482), and Vav (Y391). Y513 phosphorylation occurs first, Y482 is delayed and transient. Phosphorylated Y513 localizes exclusively to lipid rafts, while pY482 and pY391 are found both inside and outside rafts. BCR isotype (IgM vs. IgG) and co-stimulation (BCR + CD40) produce distinct phosphorylation patterns affecting downstream Vav, PI3K, and Akt signaling.","method":"Phospho-specific antibodies for each CD19 tyrosine; lipid raft fractionation; flow cytometry; co-stimulation experiments","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including phospho-specific antibodies, fractionation, and co-stimulation assays","pmids":["20101619"],"is_preprint":false},{"year":2015,"finding":"Alternative splicing of CD19 mRNA, specifically skipping of exon 2, enables resistance to CART-19 immunotherapy. The splicing factor SRSF3 is involved in exon 2 retention and its levels are lower in relapsed B-ALL. Exon 2 skipping bypasses exon 2 mutations and allows expression of an N-terminally truncated CD19 variant that fails to trigger CART-19 killing but partly rescues defects associated with CD19 loss.","method":"Pull-down/siRNA experiments identifying SRSF3; genome editing to demonstrate exon 2 skipping; flow cytometry; cytotoxicity assays; sequencing of relapse samples","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA, genome editing, functional killing assays) with mechanistic follow-up","pmids":["26516065"],"is_preprint":false},{"year":2015,"finding":"CD19 is required for TLR9-induced B cell activation. TLR9 ligands induce phosphorylation of CD19 through a MYD88/PYK2/LYN complex, which recruits PI3K and leads to phosphorylation of BTK and AKT. Inhibition of PI3K, AKT, or BTK, as well as BTK deficiency, produces TLR9 activation defects similar to CD19 deficiency, defining a CD19/PI3K/AKT/BTK axis integrating BCR and TLR9 signaling.","method":"Phospho-flow cytometry; immunoblotting; co-immunoprecipitation in CD19-deficient B cells and CD19-knockdown cell lines; B cells from patients with 1 or 2 defective CD19 alleles","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple methods (Co-IP, phospho-flow, shRNA knockdown) in human patient cells and cell lines","pmids":["26478008"],"is_preprint":false},{"year":2016,"finding":"Mst1 kinase positively regulates BCR signaling via transcriptional upregulation of CD19. Mst1 upregulates CD19 mRNA levels by regulating the transcription factor TEAD2, which directly binds to a consensus motif in the 3' UTR of cd19. Mst1 deficiency leads to reduced BCR signaling, defective BCR clustering and B cell spreading, and severe defects in MZ and germinal center B cell differentiation.","method":"Genetically manipulated mouse models (Mst1 knockout); total internal reflection fluorescence microscopy; RT-PCR; chromatin binding assays for TEAD2 at cd19 3' UTR","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with direct transcription factor binding to CD19 3' UTR and multiple functional readouts","pmids":["29296937"],"is_preprint":false},{"year":2018,"finding":"CD19 exon 2 variants (insertion or skipping) resulting from resistance to CART therapy cause protein misfolding and retention in the endoplasmic reticulum. CD19 exon 2 variant proteins acquire ER-specific high-mannose glycans but not Golgi-processed complex glycans, colocalize with ER markers (including calnexin), and fail to bind the tetraspanin CD81 (instead associating with ER-resident chaperones). This indicates the resistance mechanism operates via surface localization failure rather than pure epitope loss.","method":"Pulse-chase assays; alpha-mannosidase inhibitor assays; GFP-fusion co-localization with ER markers; mass spectrometric profiling of CD19-interacting proteins; flow cytometry with anti-VSVg antibody; ADC killing assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical methods (pulse-chase, glycan analysis, MS interactome, co-localization) in single study","pmids":["30104252"],"is_preprint":false},{"year":2018,"finding":"CD79b (Igβ) and CD19 form an alternative B cell signaling module in Burkitt lymphoma cells. In Ramos B cells lacking all other BCR components, Igβ can be expressed on the cell surface in close proximity to CD19, and signals in an ITAM-dependent manner to promote fitness and competitive growth via ITAM/PI3K signaling.","method":"CRISPR/Cas9 deletion of BCR and co-receptor genes in Ramos BL cell line; proximity assays; competitive growth assays; ITAM signaling analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — CRISPR-based genetic dissection with functional and proximity readouts","pmids":["29669863"],"is_preprint":false},{"year":1999,"finding":"CD19 cytoplasmic signaling domain mediates growth inhibition in myeloma cells. CD19 transfectants of a myeloma cell line showed slower growth, reduced colony formation, and decreased tumorigenicity in SCID mice. A truncated CD19 lacking the cytoplasmic signaling domain did not produce growth inhibition, demonstrating that the effect requires intracellular signaling, not just surface expression.","method":"Stable transfection of CD19 vs. truncated CD19 (lacking cytoplasmic domain); in vitro growth assays; soft agar colony formation; in vivo SCID mouse tumorigenicity assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — domain truncation mutagenesis with in vitro and in vivo functional readouts","pmids":["10552966"],"is_preprint":false},{"year":2022,"finding":"Expression of Golgi-resident intramembrane protease SPPL3 in malignant B cells regulates CD19 surface abundance and CAR T cell susceptibility. Loss of SPPL3 causes hyperglycosylation of CD19 that directly inhibits CAR T cell effector function and suppresses anti-tumor cytotoxicity. Overexpression of SPPL3 drives loss of CD19 protein and also enables resistance. This identifies post-translational glycosylation of CD19 as a mechanism of antigen escape.","method":"Genome-wide CRISPR screens; SPPL3 overexpression/knockout; glycosylation analysis; CAR T cell cytotoxicity assays in vitro","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genome-wide CRISPR screen validated with gain/loss-of-function experiments and mechanistic follow-up","pmids":["35690611"],"is_preprint":false},{"year":2022,"finding":"The RNA-binding protein NUDT21 limits CD19 expression by regulating CD19 mRNA polyadenylation and stability, while the transcriptional activator ZNF143 activates the CD19 promoter. NUDT21 deletion in B-ALL cells increased CD19 surface expression and enhanced sensitivity to CD19-specific CAR-T and blinatumomab. Upregulation of NUDT21 mRNA coincided with CD19 loss at disease relapse in human B-ALL patients.","method":"Genome-wide CRISPR-Cas9 screening; NUDT21 and ZNF143 deletion/overexpression; mRNA polyadenylation analysis; CAR-T and blinatumomab functional assays; patient sample analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — genome-wide CRISPR screen with mechanistic validation of mRNA regulatory mechanism and clinical correlation","pmids":["36138187"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of CD19 in complex with the FMC63 and SJ25C1 antibody binders were solved. FMC63's conformational epitope spans spatially adjacent but genetically distant loops in exons 3 and 4 of CD19. These structures guided molecular dynamics simulations to create lower- and higher-affinity CD19 binders, and CAR T cells with distinct binder affinities showed different antigen density requirements for cytolysis and different propensities for trogocytosis.","method":"Cryo-EM structure determination; molecular dynamics simulations; affinity-variant CAR T cell functional assays (cytolysis, trogocytosis)","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with functional validation through engineered affinity variants and multiple mechanistic assays","pmids":["36867678"],"is_preprint":false},{"year":2018,"finding":"Dock8 regulates BCR signaling via CD19. Dock8 deficiency reduces WASP protein and activity levels; WASP positively regulates cd19 transcription, and Dock8 also directly regulates cd19 transcription. Dock8-deficient B cells show reduced pCD19 and pBtk levels, defective BCR clustering and B cell spreading, and disrupted memory B cell activation.","method":"Dock8 knockout mouse model; human patient peripheral blood cells; confocal and TIRF microscopy; RT-PCR for cd19 transcription; phospho-CD19 and phospho-Btk flow cytometry","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function with multiple readouts, but CD19 transcriptional regulation mechanism partially inferred","pmids":["29472447"],"is_preprint":false},{"year":1994,"finding":"The Fc region of IgG1 anti-CD19 antibodies enhances cellular uptake of CD19 immunotoxins via FcγRIIa (CD32a) on B cells. IgG1-CD19 immunotoxin was ~100-fold more potent than IgG2a-IT. Removal of the Fc part equalized internalization rates. FcγRII-blocking mAbs decreased cytotoxicity of IgG1-IT but not IgG2a-IT, establishing FcγRIIa as mediating enhanced CD19 IgG1 internalization.","method":"125I-labeled mAb binding and internalization studies; FcγRII-blocking mAbs; cytotoxicity assays with class-switch variants","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — direct internalization assay with Fc blocking and isotype variants, single lab","pmids":["7516821"],"is_preprint":false},{"year":2000,"finding":"Small quantitative increases (15-29%) in CD19 cell surface expression in transgenic mice are sufficient to induce spontaneous autoantibody production (antinuclear Abs, rheumatoid factor, anti-DNA, anti-histone), demonstrating that CD19 expression levels directly set signaling thresholds controlling the balance between immunity and autoimmunity.","method":"CD19 transgenic mouse lines with defined surface expression increases; autoantibody profiling; comparison with human systemic sclerosis patients showing ~20% elevated CD19","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — precise quantitative transgenic model with multiple autoantibody readouts replicated in human patient comparison","pmids":["11086109"],"is_preprint":false},{"year":2019,"finding":"Comprehensive single-site saturation mutagenesis of the CD19 extracellular domain mapped the epitopes of CD19 antibodies FMC63, 4G7-2E3, and 3B10. FMC63's conformational epitope spans spatially adjacent but genetically distant loops in exons 3 and 4. All three antibodies have partially overlapping but distinct epitopes near the B43 antibody epitope. Removal of all N-linked glycosylation sites still permitted antibody binding in a yeast display context.","method":"Comprehensive single-site saturation mutation library screening via yeast display; flow cytometric selection; epitope mapping; thermostability variant identification","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — comprehensive mutagenesis with functional binding readout, multiple antibodies tested","pmids":["31702909"],"is_preprint":false}],"current_model":"CD19 is a type I transmembrane glycoprotein that functions as the dominant signaling component of the B cell coreceptor complex (with CD21/CR2, CD81, and CD225), physically associating with surface immunoglobulin and Bruton's tyrosine kinase to amplify BCR-induced signaling through a Lyn→CD19 tyrosine phosphorylation (Y482, Y513, Y391) loop that recruits PI3K, activates Akt and Vav, and synergistically amplifies MAP kinase activation; CD19 additionally integrates TLR9 signals via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, its surface expression level is regulated transcriptionally by ZNF143/TEAD2/Mst1 and post-transcriptionally by NUDT21-mediated mRNA polyadenylation, its cell-surface trafficking requires proper folding and CD81 binding (exon 2 integrity) and is regulated by SPPL3-dependent glycosylation, and its cryo-EM structure in complex with clinical binders (FMC63, SJ25C1) has revealed a conformational epitope spanning exons 3-4 loops that dictates CAR T cell antigen density sensitivity and trogocytosis."},"narrative":{"teleology":[{"year":1989,"claim":"The first evidence that CD19 is not an isolated surface marker but physically and functionally coupled to the BCR came from the demonstration that anti-Ig antibodies specifically co-modulate and co-cap CD19, establishing CD19 as a component of the antigen receptor complex.","evidence":"Co-modulation and co-capping assays with 15 anti-CD19 mAbs and anti-Ig on mature B cells","pmids":["2479707"],"confidence":"High","gaps":["Nature of the physical linkage between CD19 and sIg was unknown","No signaling consequences were measured","Whether other coreceptor components (CD21, CD81) were required for the association was not addressed"]},{"year":1997,"claim":"The question of what CD19 does to BCR signaling output was answered by showing that CD19 co-ligation with membrane Ig synergistically amplifies MAP kinase (ERK2, JNK, p38) activation, establishing CD19 as a positive signal amplifier rather than merely a physical accessory.","evidence":"MAP kinase activation assays with selective co-ligation of CD19 and CD22 with mIg on B cells","pmids":["9252120"],"confidence":"High","gaps":["Specific CD19 residues mediating amplification were unknown","Kinase cascade intermediates between CD19 and MAP kinases were not fully defined"]},{"year":2001,"claim":"Multiple studies converged to define the signaling architecture downstream of CD19: CD19 is required for efficient Akt activation following BCR cross-linking, physically associates with Btk to maintain its activated state, and operates in a Lyn/CD19 amplification loop whose disruption abolishes B cell hyper-responsiveness and autoimmunity.","evidence":"Akt kinase assays in CD19-deficient cells; Co-IP of CD19 and Btk; compound CD19/Lyn and CD19/Xid knockout mouse phenotyping; Ca²⁺ flux assays","pmids":["11042164","12023340","11509585"],"confidence":"High","gaps":["The hierarchy and kinetics of tyrosine phosphorylation on CD19 were not yet resolved","How the CD19/Btk interaction is regulated was unclear"]},{"year":2002,"claim":"Site-directed mutagenesis in transgenic mice demonstrated that cytoplasmic tyrosines Y482 and Y513 are essential for all major CD19 functions in vivo—B1, marginal zone, and germinal center B cell development and antibody responses—converting correlative signaling data into definitive in vivo requirements.","evidence":"CD19-knockout mice reconstituted with tyrosine-mutant CD19 transgenes; comprehensive immunological phenotyping","pmids":["12387743"],"confidence":"High","gaps":["Individual contributions of Y482 vs Y513 were not fully separated in this study","Role of Y391 in vivo was not addressed"]},{"year":2007,"claim":"The discovery that CD86 costimulatory signals converge on CD19 via Lyn phosphorylation to recruit Vav and PI3K expanded CD19's role from a BCR-specific coreceptor to an integrator of costimulatory input for IgG1 class-switch regulation.","evidence":"Co-IP of CD19 with Lyn/Vav/PI3K after CD28/Ig stimulation; adoptive transfer in RAG2-deficient mice with CD86-deficient B cells","pmids":["17641017"],"confidence":"High","gaps":["Whether other costimulatory ligands (CD80) use the same CD19-dependent pathway was not tested","The CD86→Lyn→CD19 pathway was shown only for IgG1 regulation"]},{"year":2009,"claim":"Genetic uncoupling of complement receptor CD21 from CD19 in knockin mice proved that the physical CD21–CD19 interaction is required for germinal center B cell survival and secondary antibody responses, validating the coreceptor complex model in vivo.","evidence":"Cr2 delta/delta gfp knockin mice; germinal center B cell survival and antibody titer measurements","pmids":["19706534"],"confidence":"High","gaps":["Whether CD81 independently contributes to CD19 coreceptor function in this system was not dissected","Molecular mechanism of CD21-to-CD19 signal transfer was not defined"]},{"year":2010,"claim":"Phospho-specific antibodies resolved the temporal and spatial code of CD19 tyrosine phosphorylation: Y513 (Lyn docking) is phosphorylated first and localizes to lipid rafts; Y482 (PI3K) and Y391 (Vav) follow with distinct kinetics and raft distribution, and different BCR isotypes and co-stimuli produce distinct phosphorylation patterns.","evidence":"Phospho-specific flow cytometry; lipid raft fractionation; BCR isotype and co-stimulation comparisons","pmids":["20101619"],"confidence":"High","gaps":["Phosphatases responsible for Y482 dephosphorylation were not identified","How raft partitioning of pY513 vs pY482 translates into distinct downstream outputs was not resolved"]},{"year":2015,"claim":"Two studies expanded CD19's biology beyond the BCR: CD19 was shown to be required for TLR9-induced B cell activation via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, and alternative splicing of CD19 exon 2 (regulated by SRSF3) was identified as a mechanism of resistance to CD19-directed CAR T therapy in B-ALL.","evidence":"Phospho-flow and Co-IP in CD19-deficient human B cells and patient samples; siRNA/genome editing of SRSF3 with CAR T cytotoxicity assays and relapse sample sequencing","pmids":["26478008","26516065"],"confidence":"High","gaps":["Whether CD19 integrates other TLR signals beyond TLR9 was not tested","The full repertoire of splicing factors controlling exon 2 inclusion was not mapped"]},{"year":2018,"claim":"The mechanism of exon 2 skipping-mediated resistance was shown to operate via protein misfolding and ER retention rather than simple epitope loss: exon 2-deleted CD19 acquires only high-mannose glycans, colocalizes with ER chaperones, and fails to bind CD81, precluding surface trafficking.","evidence":"Pulse-chase, glycan analysis, mass spectrometry interactome, GFP-ER co-localization, ADC killing assays","pmids":["30104252"],"confidence":"High","gaps":["Whether pharmacological chaperones could rescue surface expression of exon 2 variants was not tested","The structural basis of CD81 binding dependence on exon 2 was not resolved"]},{"year":2018,"claim":"CD79b/Igβ was shown to form an alternative signaling module with CD19 in Burkitt lymphoma cells lacking other BCR components, demonstrating that CD19 can participate in ITAM/PI3K-dependent survival signaling independently of the canonical BCR complex.","evidence":"CRISPR/Cas9 deletion of BCR components in Ramos cells; proximity assays; competitive growth assays","pmids":["29669863"],"confidence":"High","gaps":["Whether this Igβ/CD19 module operates in normal B cells or only in lymphoma was not established","The stoichiometry and structural basis of the Igβ–CD19 interaction was not defined"]},{"year":2022,"claim":"Genome-wide CRISPR screens identified two new regulators of CD19 surface expression relevant to therapy resistance: SPPL3, whose loss causes hyperglycosylation that inhibits CAR T recognition, and NUDT21, which limits CD19 mRNA stability via polyadenylation, while ZNF143 activates the CD19 promoter.","evidence":"Genome-wide CRISPR-Cas9 screens in B-ALL cells; SPPL3/NUDT21/ZNF143 gain- and loss-of-function; glycosylation analysis; mRNA polyadenylation analysis; CAR T and blinatumomab assays; patient relapse samples","pmids":["35690611","36138187"],"confidence":"High","gaps":["The specific glycan modifications on CD19 that impede CAR binding were not structurally resolved","Whether NUDT21 regulation of CD19 operates in normal B cell development was not examined"]},{"year":2023,"claim":"Cryo-EM structures of CD19 with FMC63 and SJ25C1 revealed the conformational epitope spanning exons 3–4 loops and enabled rational engineering of affinity-variant CARs, showing that binder affinity tunes antigen density sensitivity and trogocytosis propensity.","evidence":"Cryo-EM at near-atomic resolution; molecular dynamics-guided affinity variant design; CAR T functional assays","pmids":["36867678"],"confidence":"High","gaps":["Structure of full-length CD19 including the transmembrane and cytoplasmic domains is still lacking","How CD19 conformational dynamics on live B cells affect epitope accessibility was not resolved"]},{"year":null,"claim":"Key open questions include the structural basis of CD19 interaction with CD81 and CD21 in the intact coreceptor complex, the identity of phosphatases that reset CD19 tyrosine phosphorylation, whether the Igβ/CD19 alternative signaling module is physiologically relevant outside lymphoma, and how SPPL3-dependent glycosylation changes specifically impair CAR T recognition at the molecular level.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of the CD19/CD81/CD21 coreceptor complex exists","Phosphatases controlling CD19 dephosphorylation are unidentified","Physiological relevance of Igβ/CD19 module in non-malignant B cells is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,2,5,8,10]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,8,9,12,15,21]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,3,4,5,6,7,8,10,13]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,5,6,8,10]}],"complexes":["CD19/CD21/CD81/CD225 B cell coreceptor complex"],"partners":["LYN","BTK","PIK3R1","VAV1","CD81","CD79B","CD21"],"other_free_text":[]},"mechanistic_narrative":"CD19 is a B cell transmembrane glycoprotein that functions as the principal signaling amplifier of the B cell antigen receptor (BCR), integrating complement, costimulatory, and innate immune inputs to set B cell activation thresholds and control humoral immunity. CD19 physically associates with surface immunoglobulin and Bruton's tyrosine kinase (Btk), and upon BCR engagement its cytoplasmic tyrosines Y513, Y482, and Y391 are sequentially phosphorylated by Lyn, creating docking sites for PI3K, Vav, and Lyn itself; this Lyn→CD19 amplification loop drives synergistic MAP kinase activation, sustained Akt signaling, and Ca²⁺ flux, and is essential in vivo for B1, marginal zone, and germinal center B cell differentiation [PMID:2479707, PMID:12387743, PMID:20101619, PMID:11509585]. CD19 also integrates TLR9 signals via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, and its surface expression—tightly controlled transcriptionally by ZNF143, TEAD2/Mst1, and DOCK8/WASP, and post-transcriptionally by NUDT21-mediated mRNA polyadenylation and SPPL3-dependent glycosylation—directly determines the boundary between productive immunity and autoimmunity [PMID:26478008, PMID:36138187, PMID:35690611, PMID:11086109]. Alternative splicing of exon 2 (regulated by SRSF3) causes protein misfolding, ER retention, loss of CD81 binding, and failure of surface trafficking, constituting a major mechanism of antigen escape from CD19-directed CAR T cell therapy in B-ALL [PMID:26516065, PMID:30104252]."},"prefetch_data":{"uniprot":{"accession":"P15391","full_name":"B-lymphocyte antigen CD19","aliases":["B-lymphocyte surface antigen B4","Differentiation antigen CD19","T-cell surface antigen Leu-12"],"length_aa":556,"mass_kda":61.1,"function":"Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes (PubMed:29523808). Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:1373518, PubMed:16672701, PubMed:2463100). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores (PubMed:12387743, PubMed:16672701, PubMed:9317126, PubMed:9382888). Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:1373518, PubMed:2463100). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:12387743, PubMed:16672701, PubMed:9317126)","subcellular_location":"Cell membrane; Membrane raft","url":"https://www.uniprot.org/uniprotkb/P15391/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD19","classification":"Not Classified","n_dependent_lines":28,"n_total_lines":1208,"dependency_fraction":0.023178807947019868},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD19","total_profiled":1310},"omim":[{"mim_id":"621523","title":"SPONDYLOCOSTAL DYSOSTOSIS 7, AUTOSOMAL RECESSIVE; SCDO7","url":"https://www.omim.org/entry/621523"},{"mim_id":"621234","title":"ICHAD SYNDROME; ICHAD","url":"https://www.omim.org/entry/621234"},{"mim_id":"621097","title":"IMMUNODEFICIENCY 131; IMD131","url":"https://www.omim.org/entry/621097"},{"mim_id":"621068","title":"NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, POOR GROWTH, DYSMORPHIC FACIES, AND AGAMMAGLOBULINEMIA; NEDHGFA","url":"https://www.omim.org/entry/621068"},{"mim_id":"620532","title":"HYPER-IgE SYNDROME 6, AUTOSOMAL DOMINANT, WITH RECURRENT INFECTIONS; HIES6","url":"https://www.omim.org/entry/620532"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":31.2},{"tissue":"lymphoid tissue","ntpm":70.8}],"url":"https://www.proteinatlas.org/search/CD19"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P15391","domains":[{"cath_id":"2.60.40.10","chopping":"21-135_154-279","consensus_level":"medium","plddt":83.4136,"start":21,"end":279},{"cath_id":"1.20.5","chopping":"280-315","consensus_level":"medium","plddt":84.1953,"start":280,"end":315}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15391","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15391-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15391-F1-predicted_aligned_error_v6.png","plddt_mean":62.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD19","jax_strain_url":"https://www.jax.org/strain/search?query=CD19"},"sequence":{"accession":"P15391","fasta_url":"https://rest.uniprot.org/uniprotkb/P15391.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15391/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15391"}},"corpus_meta":[{"pmid":"32023374","id":"PMC_32023374","title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.","date":"2020","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32023374","citation_count":1682,"is_preprint":false},{"pmid":"26516065","id":"PMC_26516065","title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26516065","citation_count":1051,"is_preprint":false},{"pmid":"29849141","id":"PMC_29849141","title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29849141","citation_count":724,"is_preprint":false},{"pmid":"27571406","id":"PMC_27571406","title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27571406","citation_count":483,"is_preprint":false},{"pmid":"23210908","id":"PMC_23210908","title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.","date":"2012","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23210908","citation_count":427,"is_preprint":false},{"pmid":"38238616","id":"PMC_38238616","title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.","date":"2024","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38238616","citation_count":356,"is_preprint":false},{"pmid":"8528044","id":"PMC_8528044","title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.","date":"1995","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/8528044","citation_count":260,"is_preprint":false},{"pmid":"11086109","id":"PMC_11086109","title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11086109","citation_count":244,"is_preprint":false},{"pmid":"27761200","id":"PMC_27761200","title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.","date":"2016","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/27761200","citation_count":239,"is_preprint":false},{"pmid":"30387077","id":"PMC_30387077","title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.","date":"2018","source":"CNS drugs","url":"https://pubmed.ncbi.nlm.nih.gov/30387077","citation_count":208,"is_preprint":false},{"pmid":"26325036","id":"PMC_26325036","title":"CAR therapy: the CD19 paradigm.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26325036","citation_count":181,"is_preprint":false},{"pmid":"16505143","id":"PMC_16505143","title":"Lineage specification and plasticity in CD19- early B cell precursors.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16505143","citation_count":153,"is_preprint":false},{"pmid":"19798033","id":"PMC_19798033","title":"CD19: a promising B cell target for rheumatoid arthritis.","date":"2009","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19798033","citation_count":150,"is_preprint":false},{"pmid":"33010231","id":"PMC_33010231","title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33010231","citation_count":131,"is_preprint":false},{"pmid":"34002027","id":"PMC_34002027","title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/34002027","citation_count":129,"is_preprint":false},{"pmid":"22003072","id":"PMC_22003072","title":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22003072","citation_count":128,"is_preprint":false},{"pmid":"31316055","id":"PMC_31316055","title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31316055","citation_count":124,"is_preprint":false},{"pmid":"35482927","id":"PMC_35482927","title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35482927","citation_count":119,"is_preprint":false},{"pmid":"30784102","id":"PMC_30784102","title":"Toxicities of CD19 CAR-T cell immunotherapy.","date":"2019","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30784102","citation_count":112,"is_preprint":false},{"pmid":"29593838","id":"PMC_29593838","title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.","date":"2018","source":"Therapeutic advances in neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29593838","citation_count":108,"is_preprint":false},{"pmid":"12387743","id":"PMC_12387743","title":"The physiologic role of CD19 cytoplasmic tyrosines.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12387743","citation_count":104,"is_preprint":false},{"pmid":"33558546","id":"PMC_33558546","title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33558546","citation_count":103,"is_preprint":false},{"pmid":"9252120","id":"PMC_9252120","title":"Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9252120","citation_count":95,"is_preprint":false},{"pmid":"24667955","id":"PMC_24667955","title":"CD19-CAR trials.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/24667955","citation_count":94,"is_preprint":false},{"pmid":"22361174","id":"PMC_22361174","title":"CD19(+)CD1d(+)CD5(+) B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses.","date":"2012","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22361174","citation_count":94,"is_preprint":false},{"pmid":"2479707","id":"PMC_2479707","title":"CD19 is functionally and physically associated with surface immunoglobulin.","date":"1989","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2479707","citation_count":94,"is_preprint":false},{"pmid":"11042164","id":"PMC_11042164","title":"Cd19-dependent activation of Akt kinase in B-lymphocytes.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11042164","citation_count":81,"is_preprint":false},{"pmid":"30890546","id":"PMC_30890546","title":"Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30890546","citation_count":77,"is_preprint":false},{"pmid":"15778510","id":"PMC_15778510","title":"CD19 function in central and peripheral B-cell development.","date":"2005","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/15778510","citation_count":72,"is_preprint":false},{"pmid":"33077866","id":"PMC_33077866","title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.","date":"2020","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/33077866","citation_count":68,"is_preprint":false},{"pmid":"28153605","id":"PMC_28153605","title":"CD19, from bench to bedside.","date":"2017","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28153605","citation_count":68,"is_preprint":false},{"pmid":"30104252","id":"PMC_30104252","title":"CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30104252","citation_count":68,"is_preprint":false},{"pmid":"31231380","id":"PMC_31231380","title":"High TLR7 Expression Drives the Expansion of CD19+CD24hiCD38hi Transitional B Cells and Autoantibody Production in SLE Patients.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31231380","citation_count":64,"is_preprint":false},{"pmid":"29669863","id":"PMC_29669863","title":"Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/29669863","citation_count":62,"is_preprint":false},{"pmid":"35690611","id":"PMC_35690611","title":"Antigen glycosylation regulates efficacy of CAR T cells targeting CD19.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35690611","citation_count":56,"is_preprint":false},{"pmid":"36867678","id":"PMC_36867678","title":"CD19 CAR antigen engagement mechanisms and affinity tuning.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36867678","citation_count":55,"is_preprint":false},{"pmid":"34196410","id":"PMC_34196410","title":"CAR T cells: Building on the CD19 paradigm.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34196410","citation_count":55,"is_preprint":false},{"pmid":"24418477","id":"PMC_24418477","title":"Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24418477","citation_count":54,"is_preprint":false},{"pmid":"15624204","id":"PMC_15624204","title":"Diminished expression of CD19 in B-cell lymphomas.","date":"2005","source":"Cytometry. Part B, Clinical cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/15624204","citation_count":49,"is_preprint":false},{"pmid":"33228221","id":"PMC_33228221","title":"Complications after CD19+ CAR T-Cell Therapy.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33228221","citation_count":47,"is_preprint":false},{"pmid":"36138187","id":"PMC_36138187","title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36138187","citation_count":46,"is_preprint":false},{"pmid":"26478008","id":"PMC_26478008","title":"CD19 controls Toll-like receptor 9 responses in human B cells.","date":"2015","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26478008","citation_count":46,"is_preprint":false},{"pmid":"24662004","id":"PMC_24662004","title":"New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids.","date":"2014","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/24662004","citation_count":45,"is_preprint":false},{"pmid":"24442430","id":"PMC_24442430","title":"CD19 and CD32b differentially regulate human B cell responsiveness.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24442430","citation_count":44,"is_preprint":false},{"pmid":"30479356","id":"PMC_30479356","title":"Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30479356","citation_count":44,"is_preprint":false},{"pmid":"30259082","id":"PMC_30259082","title":"CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer.","date":"2018","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30259082","citation_count":44,"is_preprint":false},{"pmid":"31201998","id":"PMC_31201998","title":"Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.","date":"2019","source":"Genomics, proteomics & bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/31201998","citation_count":42,"is_preprint":false},{"pmid":"33362794","id":"PMC_33362794","title":"Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33362794","citation_count":42,"is_preprint":false},{"pmid":"23885836","id":"PMC_23885836","title":"Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.","date":"2013","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/23885836","citation_count":41,"is_preprint":false},{"pmid":"12023340","id":"PMC_12023340","title":"Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12023340","citation_count":38,"is_preprint":false},{"pmid":"37744005","id":"PMC_37744005","title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.","date":"2023","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/37744005","citation_count":36,"is_preprint":false},{"pmid":"10552966","id":"PMC_10552966","title":"Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10552966","citation_count":36,"is_preprint":false},{"pmid":"31702909","id":"PMC_31702909","title":"Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31702909","citation_count":35,"is_preprint":false},{"pmid":"31899793","id":"PMC_31899793","title":"How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31899793","citation_count":35,"is_preprint":false},{"pmid":"11509585","id":"PMC_11509585","title":"A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11509585","citation_count":35,"is_preprint":false},{"pmid":"39589371","id":"PMC_39589371","title":"Aggressive Lymphoma after CD19 CAR T-Cell Therapy.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39589371","citation_count":34,"is_preprint":false},{"pmid":"23360526","id":"PMC_23360526","title":"A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.","date":"2013","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23360526","citation_count":34,"is_preprint":false},{"pmid":"31110096","id":"PMC_31110096","title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.","date":"2019","source":"BMJ open","url":"https://pubmed.ncbi.nlm.nih.gov/31110096","citation_count":33,"is_preprint":false},{"pmid":"16430470","id":"PMC_16430470","title":"Loss of CD19 expression in B-cell neoplasms.","date":"2006","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/16430470","citation_count":32,"is_preprint":false},{"pmid":"12403344","id":"PMC_12403344","title":"Role of CD19 signal transduction in B cell biology.","date":"2002","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/12403344","citation_count":32,"is_preprint":false},{"pmid":"19706534","id":"PMC_19706534","title":"Uncoupling CD21 and CD19 of the B-cell coreceptor.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19706534","citation_count":32,"is_preprint":false},{"pmid":"29335495","id":"PMC_29335495","title":"Dysfunction of CD19+CD24hiCD27+ B regulatory cells in patients with bullous pemphigoid.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29335495","citation_count":32,"is_preprint":false},{"pmid":"32311088","id":"PMC_32311088","title":"Deficit of circulating CD19+ CD24hi CD38hi regulatory B cells in severe aplastic anaemia.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32311088","citation_count":30,"is_preprint":false},{"pmid":"31242389","id":"PMC_31242389","title":"Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.","date":"2019","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/31242389","citation_count":30,"is_preprint":false},{"pmid":"28821531","id":"PMC_28821531","title":"CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.","date":"2017","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/28821531","citation_count":30,"is_preprint":false},{"pmid":"35421218","id":"PMC_35421218","title":"CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35421218","citation_count":29,"is_preprint":false},{"pmid":"36945773","id":"PMC_36945773","title":"Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.","date":"2023","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36945773","citation_count":29,"is_preprint":false},{"pmid":"33656536","id":"PMC_33656536","title":"HLA-haploidentical TCRαβ+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33656536","citation_count":29,"is_preprint":false},{"pmid":"17641017","id":"PMC_17641017","title":"CD86 regulates IgG1 production via a CD19-dependent mechanism.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17641017","citation_count":28,"is_preprint":false},{"pmid":"35362043","id":"PMC_35362043","title":"Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.","date":"2022","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35362043","citation_count":27,"is_preprint":false},{"pmid":"33974997","id":"PMC_33974997","title":"Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33974997","citation_count":27,"is_preprint":false},{"pmid":"26103922","id":"PMC_26103922","title":"BAFF-driven autoimmunity requires CD19 expression.","date":"2015","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/26103922","citation_count":26,"is_preprint":false},{"pmid":"29296937","id":"PMC_29296937","title":"Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels.","date":"2016","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29296937","citation_count":26,"is_preprint":false},{"pmid":"20445561","id":"PMC_20445561","title":"B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele.","date":"2010","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20445561","citation_count":26,"is_preprint":false},{"pmid":"37518011","id":"PMC_37518011","title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37518011","citation_count":25,"is_preprint":false},{"pmid":"38608514","id":"PMC_38608514","title":"Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma.","date":"2024","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38608514","citation_count":24,"is_preprint":false},{"pmid":"24023523","id":"PMC_24023523","title":"Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.","date":"2013","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/24023523","citation_count":24,"is_preprint":false},{"pmid":"28985543","id":"PMC_28985543","title":"Evaluation of interleukin-10 producing CD19+ B cells in human gingival tissue.","date":"2017","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/28985543","citation_count":23,"is_preprint":false},{"pmid":"7516821","id":"PMC_7516821","title":"Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7516821","citation_count":23,"is_preprint":false},{"pmid":"29472447","id":"PMC_29472447","title":"Dock8 regulates BCR signaling and activation of memory B cells via WASP and CD19.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29472447","citation_count":22,"is_preprint":false},{"pmid":"28306193","id":"PMC_28306193","title":"Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28306193","citation_count":22,"is_preprint":false},{"pmid":"35280988","id":"PMC_35280988","title":"CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35280988","citation_count":21,"is_preprint":false},{"pmid":"37879074","id":"PMC_37879074","title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37879074","citation_count":20,"is_preprint":false},{"pmid":"25755168","id":"PMC_25755168","title":"CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.","date":"2015","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25755168","citation_count":20,"is_preprint":false},{"pmid":"20101619","id":"PMC_20101619","title":"Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20101619","citation_count":20,"is_preprint":false},{"pmid":"29973221","id":"PMC_29973221","title":"Frequency of CD19+CD24hiCD38hi regulatory B cells is decreased in peripheral blood and synovial fluid of patients with juvenile idiopathic arthritis: a preliminary study.","date":"2018","source":"Pediatric rheumatology online journal","url":"https://pubmed.ncbi.nlm.nih.gov/29973221","citation_count":19,"is_preprint":false},{"pmid":"31598989","id":"PMC_31598989","title":"The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19+ CD25+ Bregs and suppresses the secretion of IL-10 in patients with allergic rhinitis.","date":"2019","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31598989","citation_count":19,"is_preprint":false},{"pmid":"33205351","id":"PMC_33205351","title":"Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells.","date":"2020","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/33205351","citation_count":19,"is_preprint":false},{"pmid":"36251156","id":"PMC_36251156","title":"Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.","date":"2022","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36251156","citation_count":18,"is_preprint":false},{"pmid":"31181422","id":"PMC_31181422","title":"Decreased number of CD19+CD24hiCD38hi regulatory B cells in Diabetic nephropathy.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31181422","citation_count":18,"is_preprint":false},{"pmid":"36494762","id":"PMC_36494762","title":"CD19+CD24highCD27+ B cell and interleukin 35 as potential biomarkers of disease activity in systemic lupus erythematosus patients.","date":"2022","source":"Advances in rheumatology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36494762","citation_count":18,"is_preprint":false},{"pmid":"35405368","id":"PMC_35405368","title":"Haploidentical Stem Cell Transplantation After TCR-αβ+ and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease.","date":"2022","source":"Transplantation and cellular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35405368","citation_count":18,"is_preprint":false},{"pmid":"7693581","id":"PMC_7693581","title":"Activated CD19+ B cell lamina propria lymphocytes in ulcerative colitis.","date":"1993","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7693581","citation_count":18,"is_preprint":false},{"pmid":"35420296","id":"PMC_35420296","title":"Interleukin-35 promotes Breg expansion and interleukin-10 production in CD19+ B cells in patients with ankylosing spondylitis.","date":"2022","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/35420296","citation_count":18,"is_preprint":false},{"pmid":"36409926","id":"PMC_36409926","title":"Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.","date":"2023","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36409926","citation_count":17,"is_preprint":false},{"pmid":"36636644","id":"PMC_36636644","title":"Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.","date":"2023","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/36636644","citation_count":17,"is_preprint":false},{"pmid":"34122428","id":"PMC_34122428","title":"Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34122428","citation_count":17,"is_preprint":false},{"pmid":"29892548","id":"PMC_29892548","title":"Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia.","date":"2018","source":"Leukemia research reports","url":"https://pubmed.ncbi.nlm.nih.gov/29892548","citation_count":17,"is_preprint":false},{"pmid":"30075290","id":"PMC_30075290","title":"Deficiencies in the CD19 complex.","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/30075290","citation_count":16,"is_preprint":false},{"pmid":"30187806","id":"PMC_30187806","title":"TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data.","date":"2018","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/30187806","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48196,"output_tokens":5991,"usd":0.117226},"stage2":{"model":"claude-opus-4-6","input_tokens":9560,"output_tokens":3599,"usd":0.206662},"total_usd":0.323888,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CD19 is physically and functionally associated with surface immunoglobulin (sIg) on B cells. Anti-Ig antibodies cause specific, rapid, reversible, and unidirectional co-modulation of CD19, with anti-Ig co-capping and internalizing anti-CD19 mAb, suggesting CD19 is a component of the B cell antigen receptor complex that facilitates signal transduction by sIg-antigen complexes.\",\n      \"method\": \"Co-modulation assays, co-capping experiments with 15 CD19-specific mAbs and anti-Ig mAbs on mature B cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-modulation with multiple orthogonal antibodies, replicated across multiple B cell types and CD19 epitopes\",\n      \"pmids\": [\"2479707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD19 and CD22 have counterregulatory effects on MAP kinase (ERK2, JNK, p38) activation downstream of membrane immunoglobulin (mIg). Co-ligation of CD19 with mIg synergistically amplifies MAP kinase activation, while CD22 suppresses MAP kinase activation when cross-linked to mIg. This regulation is dependent on the proximity of these coreceptors to the antigen receptor.\",\n      \"method\": \"MAP kinase activation assays with selective co-ligation and cross-linking of CD19 and CD22 with mIg on B cells\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with multiple kinase readouts and reciprocal co-ligation controls\",\n      \"pmids\": [\"9252120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD19 is necessary for efficient activation of Akt kinase following BCR cross-linking or Igβ ligation in B lymphocytes. In the absence of CD19, Akt kinase activity is reduced and transient. Co-ligation of CD19 with surface immunoglobulin leads to dose-dependent augmented Akt activity, placing CD19 as a key regulator of PI3K-dependent Akt survival signaling.\",\n      \"method\": \"Akt kinase activity assays in CD19-deficient B lymphoma cells and mouse splenic B cells; co-ligation experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct kinase assay in both cell line and primary cells with genetic loss-of-function, replicated with co-ligation\",\n      \"pmids\": [\"11042164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD19 deficiency suppresses the hyper-responsive B cell phenotype and autoimmunity (serum autoantibodies, glomerulonephritis) in Lyn-deficient mice, demonstrating that a CD19/Lyn amplification loop is a major regulator of B cell signaling thresholds. Tyrosine phosphorylation of Fyn and BCR-induced Ca2+ responses were dramatically reduced in CD19/Lyn double-deficient B cells.\",\n      \"method\": \"Compound knockout mouse model (CD19/Lyn double-deficient); immunological phenotyping, Ca2+ flux assays, tyrosine phosphorylation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple molecular and cellular phenotypic readouts\",\n      \"pmids\": [\"11509585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD19 cytoplasmic tyrosines Y482 and Y513 are essential for all major functions of CD19 in vivo, including differentiation of B1 and marginal zone B cells, T-dependent and -independent antibody responses, and germinal center B cell maturation. Mutation of Y482/Y513 reduces proliferation in germinal center B cells.\",\n      \"method\": \"CD19-knockout mice expressing transgenic CD19 constructs with specific tyrosine mutations; immunological phenotyping in vivo\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vivo site-directed mutagenesis of specific residues combined with comprehensive phenotypic analysis\",\n      \"pmids\": [\"12387743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD19 physically associates with Bruton's tyrosine kinase (Btk) following BCR engagement in A20 B cells. CD19 expression maintains Btk in an activated state following BCR engagement, rather than being required for initial Btk phosphorylation. CD19-induced Ca2+ responses require downstream Btk function, and CD19 deficiency combined with Btk mutation (Xid) has additive inhibitory effects.\",\n      \"method\": \"Co-immunoprecipitation of CD19 and Btk; genetic compound mouse models (CD19−/− × Xid); Ca2+ flux assays; PI3K/Akt activation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus genetic compound mutants with multiple functional readouts\",\n      \"pmids\": [\"12023340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD86 signals through CD19 to activate PI3K and increase IgG1 production in B cells. CD28/Ig-mediated signaling increases phosphorylation of Lyn and CD19 and the association of Lyn, Vav, and PI3K with CD19. This effect is absent in CD86- or CD19-deficient B cells, placing CD86→Lyn→CD19 upstream of PI3K in IgG1 regulation.\",\n      \"method\": \"Co-immunoprecipitation of CD19 with Lyn/Vav/PI3K; adoptive transfer experiments in RAG2-deficient mice with CD86-deficient B cells; in vitro stimulation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus genetic loss-of-function with in vivo reconstitution\",\n      \"pmids\": [\"17641017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Uncoupling CD21 (complement receptor) from CD19 via knockin mice expressing mutant receptors that bind C3 ligands but cannot signal through CD19 significantly diminishes survival of germinal center B cells and secondary antibody titers, confirming that the physical and functional interaction between CD21/CR and CD19 is necessary for coreceptor activity in humoral immunity.\",\n      \"method\": \"Knockin mouse model (Cr2 delta/delta gfp); germinal center B cell survival assays; antibody titer measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic uncoupling with defined cellular and humoral phenotypic consequences\",\n      \"pmids\": [\"19706534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD19 cytoplasmic tyrosines Y513, Y482, and Y391 are differentially phosphorylated during B cell activation, serving as docking sites for Lyn (Y513), PI3K (Y482), and Vav (Y391). Y513 phosphorylation occurs first, Y482 is delayed and transient. Phosphorylated Y513 localizes exclusively to lipid rafts, while pY482 and pY391 are found both inside and outside rafts. BCR isotype (IgM vs. IgG) and co-stimulation (BCR + CD40) produce distinct phosphorylation patterns affecting downstream Vav, PI3K, and Akt signaling.\",\n      \"method\": \"Phospho-specific antibodies for each CD19 tyrosine; lipid raft fractionation; flow cytometry; co-stimulation experiments\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including phospho-specific antibodies, fractionation, and co-stimulation assays\",\n      \"pmids\": [\"20101619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Alternative splicing of CD19 mRNA, specifically skipping of exon 2, enables resistance to CART-19 immunotherapy. The splicing factor SRSF3 is involved in exon 2 retention and its levels are lower in relapsed B-ALL. Exon 2 skipping bypasses exon 2 mutations and allows expression of an N-terminally truncated CD19 variant that fails to trigger CART-19 killing but partly rescues defects associated with CD19 loss.\",\n      \"method\": \"Pull-down/siRNA experiments identifying SRSF3; genome editing to demonstrate exon 2 skipping; flow cytometry; cytotoxicity assays; sequencing of relapse samples\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA, genome editing, functional killing assays) with mechanistic follow-up\",\n      \"pmids\": [\"26516065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD19 is required for TLR9-induced B cell activation. TLR9 ligands induce phosphorylation of CD19 through a MYD88/PYK2/LYN complex, which recruits PI3K and leads to phosphorylation of BTK and AKT. Inhibition of PI3K, AKT, or BTK, as well as BTK deficiency, produces TLR9 activation defects similar to CD19 deficiency, defining a CD19/PI3K/AKT/BTK axis integrating BCR and TLR9 signaling.\",\n      \"method\": \"Phospho-flow cytometry; immunoblotting; co-immunoprecipitation in CD19-deficient B cells and CD19-knockdown cell lines; B cells from patients with 1 or 2 defective CD19 alleles\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (Co-IP, phospho-flow, shRNA knockdown) in human patient cells and cell lines\",\n      \"pmids\": [\"26478008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Mst1 kinase positively regulates BCR signaling via transcriptional upregulation of CD19. Mst1 upregulates CD19 mRNA levels by regulating the transcription factor TEAD2, which directly binds to a consensus motif in the 3' UTR of cd19. Mst1 deficiency leads to reduced BCR signaling, defective BCR clustering and B cell spreading, and severe defects in MZ and germinal center B cell differentiation.\",\n      \"method\": \"Genetically manipulated mouse models (Mst1 knockout); total internal reflection fluorescence microscopy; RT-PCR; chromatin binding assays for TEAD2 at cd19 3' UTR\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with direct transcription factor binding to CD19 3' UTR and multiple functional readouts\",\n      \"pmids\": [\"29296937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD19 exon 2 variants (insertion or skipping) resulting from resistance to CART therapy cause protein misfolding and retention in the endoplasmic reticulum. CD19 exon 2 variant proteins acquire ER-specific high-mannose glycans but not Golgi-processed complex glycans, colocalize with ER markers (including calnexin), and fail to bind the tetraspanin CD81 (instead associating with ER-resident chaperones). This indicates the resistance mechanism operates via surface localization failure rather than pure epitope loss.\",\n      \"method\": \"Pulse-chase assays; alpha-mannosidase inhibitor assays; GFP-fusion co-localization with ER markers; mass spectrometric profiling of CD19-interacting proteins; flow cytometry with anti-VSVg antibody; ADC killing assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods (pulse-chase, glycan analysis, MS interactome, co-localization) in single study\",\n      \"pmids\": [\"30104252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD79b (Igβ) and CD19 form an alternative B cell signaling module in Burkitt lymphoma cells. In Ramos B cells lacking all other BCR components, Igβ can be expressed on the cell surface in close proximity to CD19, and signals in an ITAM-dependent manner to promote fitness and competitive growth via ITAM/PI3K signaling.\",\n      \"method\": \"CRISPR/Cas9 deletion of BCR and co-receptor genes in Ramos BL cell line; proximity assays; competitive growth assays; ITAM signaling analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-based genetic dissection with functional and proximity readouts\",\n      \"pmids\": [\"29669863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CD19 cytoplasmic signaling domain mediates growth inhibition in myeloma cells. CD19 transfectants of a myeloma cell line showed slower growth, reduced colony formation, and decreased tumorigenicity in SCID mice. A truncated CD19 lacking the cytoplasmic signaling domain did not produce growth inhibition, demonstrating that the effect requires intracellular signaling, not just surface expression.\",\n      \"method\": \"Stable transfection of CD19 vs. truncated CD19 (lacking cytoplasmic domain); in vitro growth assays; soft agar colony formation; in vivo SCID mouse tumorigenicity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain truncation mutagenesis with in vitro and in vivo functional readouts\",\n      \"pmids\": [\"10552966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Expression of Golgi-resident intramembrane protease SPPL3 in malignant B cells regulates CD19 surface abundance and CAR T cell susceptibility. Loss of SPPL3 causes hyperglycosylation of CD19 that directly inhibits CAR T cell effector function and suppresses anti-tumor cytotoxicity. Overexpression of SPPL3 drives loss of CD19 protein and also enables resistance. This identifies post-translational glycosylation of CD19 as a mechanism of antigen escape.\",\n      \"method\": \"Genome-wide CRISPR screens; SPPL3 overexpression/knockout; glycosylation analysis; CAR T cell cytotoxicity assays in vitro\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen validated with gain/loss-of-function experiments and mechanistic follow-up\",\n      \"pmids\": [\"35690611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The RNA-binding protein NUDT21 limits CD19 expression by regulating CD19 mRNA polyadenylation and stability, while the transcriptional activator ZNF143 activates the CD19 promoter. NUDT21 deletion in B-ALL cells increased CD19 surface expression and enhanced sensitivity to CD19-specific CAR-T and blinatumomab. Upregulation of NUDT21 mRNA coincided with CD19 loss at disease relapse in human B-ALL patients.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screening; NUDT21 and ZNF143 deletion/overexpression; mRNA polyadenylation analysis; CAR-T and blinatumomab functional assays; patient sample analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen with mechanistic validation of mRNA regulatory mechanism and clinical correlation\",\n      \"pmids\": [\"36138187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of CD19 in complex with the FMC63 and SJ25C1 antibody binders were solved. FMC63's conformational epitope spans spatially adjacent but genetically distant loops in exons 3 and 4 of CD19. These structures guided molecular dynamics simulations to create lower- and higher-affinity CD19 binders, and CAR T cells with distinct binder affinities showed different antigen density requirements for cytolysis and different propensities for trogocytosis.\",\n      \"method\": \"Cryo-EM structure determination; molecular dynamics simulations; affinity-variant CAR T cell functional assays (cytolysis, trogocytosis)\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with functional validation through engineered affinity variants and multiple mechanistic assays\",\n      \"pmids\": [\"36867678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dock8 regulates BCR signaling via CD19. Dock8 deficiency reduces WASP protein and activity levels; WASP positively regulates cd19 transcription, and Dock8 also directly regulates cd19 transcription. Dock8-deficient B cells show reduced pCD19 and pBtk levels, defective BCR clustering and B cell spreading, and disrupted memory B cell activation.\",\n      \"method\": \"Dock8 knockout mouse model; human patient peripheral blood cells; confocal and TIRF microscopy; RT-PCR for cd19 transcription; phospho-CD19 and phospho-Btk flow cytometry\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple readouts, but CD19 transcriptional regulation mechanism partially inferred\",\n      \"pmids\": [\"29472447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The Fc region of IgG1 anti-CD19 antibodies enhances cellular uptake of CD19 immunotoxins via FcγRIIa (CD32a) on B cells. IgG1-CD19 immunotoxin was ~100-fold more potent than IgG2a-IT. Removal of the Fc part equalized internalization rates. FcγRII-blocking mAbs decreased cytotoxicity of IgG1-IT but not IgG2a-IT, establishing FcγRIIa as mediating enhanced CD19 IgG1 internalization.\",\n      \"method\": \"125I-labeled mAb binding and internalization studies; FcγRII-blocking mAbs; cytotoxicity assays with class-switch variants\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct internalization assay with Fc blocking and isotype variants, single lab\",\n      \"pmids\": [\"7516821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Small quantitative increases (15-29%) in CD19 cell surface expression in transgenic mice are sufficient to induce spontaneous autoantibody production (antinuclear Abs, rheumatoid factor, anti-DNA, anti-histone), demonstrating that CD19 expression levels directly set signaling thresholds controlling the balance between immunity and autoimmunity.\",\n      \"method\": \"CD19 transgenic mouse lines with defined surface expression increases; autoantibody profiling; comparison with human systemic sclerosis patients showing ~20% elevated CD19\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — precise quantitative transgenic model with multiple autoantibody readouts replicated in human patient comparison\",\n      \"pmids\": [\"11086109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Comprehensive single-site saturation mutagenesis of the CD19 extracellular domain mapped the epitopes of CD19 antibodies FMC63, 4G7-2E3, and 3B10. FMC63's conformational epitope spans spatially adjacent but genetically distant loops in exons 3 and 4. All three antibodies have partially overlapping but distinct epitopes near the B43 antibody epitope. Removal of all N-linked glycosylation sites still permitted antibody binding in a yeast display context.\",\n      \"method\": \"Comprehensive single-site saturation mutation library screening via yeast display; flow cytometric selection; epitope mapping; thermostability variant identification\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive mutagenesis with functional binding readout, multiple antibodies tested\",\n      \"pmids\": [\"31702909\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD19 is a type I transmembrane glycoprotein that functions as the dominant signaling component of the B cell coreceptor complex (with CD21/CR2, CD81, and CD225), physically associating with surface immunoglobulin and Bruton's tyrosine kinase to amplify BCR-induced signaling through a Lyn→CD19 tyrosine phosphorylation (Y482, Y513, Y391) loop that recruits PI3K, activates Akt and Vav, and synergistically amplifies MAP kinase activation; CD19 additionally integrates TLR9 signals via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, its surface expression level is regulated transcriptionally by ZNF143/TEAD2/Mst1 and post-transcriptionally by NUDT21-mediated mRNA polyadenylation, its cell-surface trafficking requires proper folding and CD81 binding (exon 2 integrity) and is regulated by SPPL3-dependent glycosylation, and its cryo-EM structure in complex with clinical binders (FMC63, SJ25C1) has revealed a conformational epitope spanning exons 3-4 loops that dictates CAR T cell antigen density sensitivity and trogocytosis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD19 is a B cell transmembrane glycoprotein that functions as the principal signaling amplifier of the B cell antigen receptor (BCR), integrating complement, costimulatory, and innate immune inputs to set B cell activation thresholds and control humoral immunity. CD19 physically associates with surface immunoglobulin and Bruton's tyrosine kinase (Btk), and upon BCR engagement its cytoplasmic tyrosines Y513, Y482, and Y391 are sequentially phosphorylated by Lyn, creating docking sites for PI3K, Vav, and Lyn itself; this Lyn→CD19 amplification loop drives synergistic MAP kinase activation, sustained Akt signaling, and Ca²⁺ flux, and is essential in vivo for B1, marginal zone, and germinal center B cell differentiation [PMID:2479707, PMID:12387743, PMID:20101619, PMID:11509585]. CD19 also integrates TLR9 signals via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, and its surface expression—tightly controlled transcriptionally by ZNF143, TEAD2/Mst1, and DOCK8/WASP, and post-transcriptionally by NUDT21-mediated mRNA polyadenylation and SPPL3-dependent glycosylation—directly determines the boundary between productive immunity and autoimmunity [PMID:26478008, PMID:36138187, PMID:35690611, PMID:11086109]. Alternative splicing of exon 2 (regulated by SRSF3) causes protein misfolding, ER retention, loss of CD81 binding, and failure of surface trafficking, constituting a major mechanism of antigen escape from CD19-directed CAR T cell therapy in B-ALL [PMID:26516065, PMID:30104252].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"The first evidence that CD19 is not an isolated surface marker but physically and functionally coupled to the BCR came from the demonstration that anti-Ig antibodies specifically co-modulate and co-cap CD19, establishing CD19 as a component of the antigen receptor complex.\",\n      \"evidence\": \"Co-modulation and co-capping assays with 15 anti-CD19 mAbs and anti-Ig on mature B cells\",\n      \"pmids\": [\"2479707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the physical linkage between CD19 and sIg was unknown\", \"No signaling consequences were measured\", \"Whether other coreceptor components (CD21, CD81) were required for the association was not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The question of what CD19 does to BCR signaling output was answered by showing that CD19 co-ligation with membrane Ig synergistically amplifies MAP kinase (ERK2, JNK, p38) activation, establishing CD19 as a positive signal amplifier rather than merely a physical accessory.\",\n      \"evidence\": \"MAP kinase activation assays with selective co-ligation of CD19 and CD22 with mIg on B cells\",\n      \"pmids\": [\"9252120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific CD19 residues mediating amplification were unknown\", \"Kinase cascade intermediates between CD19 and MAP kinases were not fully defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Multiple studies converged to define the signaling architecture downstream of CD19: CD19 is required for efficient Akt activation following BCR cross-linking, physically associates with Btk to maintain its activated state, and operates in a Lyn/CD19 amplification loop whose disruption abolishes B cell hyper-responsiveness and autoimmunity.\",\n      \"evidence\": \"Akt kinase assays in CD19-deficient cells; Co-IP of CD19 and Btk; compound CD19/Lyn and CD19/Xid knockout mouse phenotyping; Ca²⁺ flux assays\",\n      \"pmids\": [\"11042164\", \"12023340\", \"11509585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The hierarchy and kinetics of tyrosine phosphorylation on CD19 were not yet resolved\", \"How the CD19/Btk interaction is regulated was unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Site-directed mutagenesis in transgenic mice demonstrated that cytoplasmic tyrosines Y482 and Y513 are essential for all major CD19 functions in vivo—B1, marginal zone, and germinal center B cell development and antibody responses—converting correlative signaling data into definitive in vivo requirements.\",\n      \"evidence\": \"CD19-knockout mice reconstituted with tyrosine-mutant CD19 transgenes; comprehensive immunological phenotyping\",\n      \"pmids\": [\"12387743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of Y482 vs Y513 were not fully separated in this study\", \"Role of Y391 in vivo was not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The discovery that CD86 costimulatory signals converge on CD19 via Lyn phosphorylation to recruit Vav and PI3K expanded CD19's role from a BCR-specific coreceptor to an integrator of costimulatory input for IgG1 class-switch regulation.\",\n      \"evidence\": \"Co-IP of CD19 with Lyn/Vav/PI3K after CD28/Ig stimulation; adoptive transfer in RAG2-deficient mice with CD86-deficient B cells\",\n      \"pmids\": [\"17641017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other costimulatory ligands (CD80) use the same CD19-dependent pathway was not tested\", \"The CD86→Lyn→CD19 pathway was shown only for IgG1 regulation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic uncoupling of complement receptor CD21 from CD19 in knockin mice proved that the physical CD21–CD19 interaction is required for germinal center B cell survival and secondary antibody responses, validating the coreceptor complex model in vivo.\",\n      \"evidence\": \"Cr2 delta/delta gfp knockin mice; germinal center B cell survival and antibody titer measurements\",\n      \"pmids\": [\"19706534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD81 independently contributes to CD19 coreceptor function in this system was not dissected\", \"Molecular mechanism of CD21-to-CD19 signal transfer was not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Phospho-specific antibodies resolved the temporal and spatial code of CD19 tyrosine phosphorylation: Y513 (Lyn docking) is phosphorylated first and localizes to lipid rafts; Y482 (PI3K) and Y391 (Vav) follow with distinct kinetics and raft distribution, and different BCR isotypes and co-stimuli produce distinct phosphorylation patterns.\",\n      \"evidence\": \"Phospho-specific flow cytometry; lipid raft fractionation; BCR isotype and co-stimulation comparisons\",\n      \"pmids\": [\"20101619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatases responsible for Y482 dephosphorylation were not identified\", \"How raft partitioning of pY513 vs pY482 translates into distinct downstream outputs was not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Two studies expanded CD19's biology beyond the BCR: CD19 was shown to be required for TLR9-induced B cell activation via a MYD88/PYK2/LYN/PI3K/BTK/AKT axis, and alternative splicing of CD19 exon 2 (regulated by SRSF3) was identified as a mechanism of resistance to CD19-directed CAR T therapy in B-ALL.\",\n      \"evidence\": \"Phospho-flow and Co-IP in CD19-deficient human B cells and patient samples; siRNA/genome editing of SRSF3 with CAR T cytotoxicity assays and relapse sample sequencing\",\n      \"pmids\": [\"26478008\", \"26516065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD19 integrates other TLR signals beyond TLR9 was not tested\", \"The full repertoire of splicing factors controlling exon 2 inclusion was not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The mechanism of exon 2 skipping-mediated resistance was shown to operate via protein misfolding and ER retention rather than simple epitope loss: exon 2-deleted CD19 acquires only high-mannose glycans, colocalizes with ER chaperones, and fails to bind CD81, precluding surface trafficking.\",\n      \"evidence\": \"Pulse-chase, glycan analysis, mass spectrometry interactome, GFP-ER co-localization, ADC killing assays\",\n      \"pmids\": [\"30104252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pharmacological chaperones could rescue surface expression of exon 2 variants was not tested\", \"The structural basis of CD81 binding dependence on exon 2 was not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CD79b/Igβ was shown to form an alternative signaling module with CD19 in Burkitt lymphoma cells lacking other BCR components, demonstrating that CD19 can participate in ITAM/PI3K-dependent survival signaling independently of the canonical BCR complex.\",\n      \"evidence\": \"CRISPR/Cas9 deletion of BCR components in Ramos cells; proximity assays; competitive growth assays\",\n      \"pmids\": [\"29669863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this Igβ/CD19 module operates in normal B cells or only in lymphoma was not established\", \"The stoichiometry and structural basis of the Igβ–CD19 interaction was not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide CRISPR screens identified two new regulators of CD19 surface expression relevant to therapy resistance: SPPL3, whose loss causes hyperglycosylation that inhibits CAR T recognition, and NUDT21, which limits CD19 mRNA stability via polyadenylation, while ZNF143 activates the CD19 promoter.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 screens in B-ALL cells; SPPL3/NUDT21/ZNF143 gain- and loss-of-function; glycosylation analysis; mRNA polyadenylation analysis; CAR T and blinatumomab assays; patient relapse samples\",\n      \"pmids\": [\"35690611\", \"36138187\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific glycan modifications on CD19 that impede CAR binding were not structurally resolved\", \"Whether NUDT21 regulation of CD19 operates in normal B cell development was not examined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of CD19 with FMC63 and SJ25C1 revealed the conformational epitope spanning exons 3–4 loops and enabled rational engineering of affinity-variant CARs, showing that binder affinity tunes antigen density sensitivity and trogocytosis propensity.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution; molecular dynamics-guided affinity variant design; CAR T functional assays\",\n      \"pmids\": [\"36867678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length CD19 including the transmembrane and cytoplasmic domains is still lacking\", \"How CD19 conformational dynamics on live B cells affect epitope accessibility was not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of CD19 interaction with CD81 and CD21 in the intact coreceptor complex, the identity of phosphatases that reset CD19 tyrosine phosphorylation, whether the Igβ/CD19 alternative signaling module is physiologically relevant outside lymphoma, and how SPPL3-dependent glycosylation changes specifically impair CAR T recognition at the molecular level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the CD19/CD81/CD21 coreceptor complex exists\", \"Phosphatases controlling CD19 dephosphorylation are unidentified\", \"Physiological relevance of Igβ/CD19 module in non-malignant B cells is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 2, 5, 8, 10]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 8, 9, 12, 15, 21]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 5, 6, 8, 10]}\n    ],\n    \"complexes\": [\n      \"CD19/CD21/CD81/CD225 B cell coreceptor complex\"\n    ],\n    \"partners\": [\n      \"LYN\",\n      \"BTK\",\n      \"PIK3R1\",\n      \"VAV1\",\n      \"CD81\",\n      \"CD79B\",\n      \"CD21\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}